# A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine

> **NCT05519839** · PHASE2 · COMPLETED · sponsor: **Novavax** · enrollment: 1579 (actual)

## Conditions studied

- COVID-19
- Influenza

## Interventions

- **DRUG:** qNIV Vaccine with Matrix-M Adjuvant
- **DRUG:** Influenza Vaccine
- **DRUG:** CIC Vaccine with Matrix-M Adjuvant
- **OTHER:** Placebo Comparator
- **DRUG:** SARS-CoV-2 rS Vaccine with Matrix-M Adjuvant

## Key facts

- **NCT ID:** NCT05519839
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-30
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-12-24
- **Target enrollment:** 1579 (ACTUAL)
- **Last updated:** 2024-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05519839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05519839, "A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05519839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*